Skip to main content

MDxHealth SA (MDXH)

MDxHealth will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)19.31M
Net Income (ttm)-28.25M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Price Targetn/a
Earnings Daten/a

About MDXH

MDxHealth is a commercial-stage precision diagnostics company committed to providing non-invasive, clinically actionable and cost-effective urologic solutions to improve patient care. Our novel prostate cancer genomic testing solutions, SelectMDx and ConfirmMDx, provide physicians with a clear clinical pathway to accurately identify clinically significant prostate cancer while minimizing the use of invasive procedures that are prone to complications. Our unique approach combines advanced clinical modeling with genomic data to provide each patie...

IndustryHealth Care Providers & Services
IPO DatePending
CEOMichael K. McGarrity
Stock ExchangeNASDAQ
Ticker SymbolMDXH
Full Company Profile

Financial Performance

In 2020, MDxHealth's revenue was $18.46 million, an increase of 56.64% compared to the previous year's $11.79 million. Losses were -$28.66 million, -33.50% less than in 2019.

Financial Statements


Belgium-listed diagnostics company MDxHealth files for a $30 million US IPO

MDxHealth, a Belgian provider of genomic testing products for prostate cancer, filed on Wednesday with the SEC to raise up to $30 million in an initial public offering.

1 week ago - Renaissance Capital

MDxHealth files Registration Statement for Proposed Initial Public Offering in the United States

MDxHealth files Registration Statement for Proposed Initial...

1 week ago - GlobeNewswire

MDxHealth IPO Registration Document (F-1)

MDxHealth SA has filed to go public with an IPO on the NASDAQ.

1 week ago - SEC